MORE►
NanoScope Technologies
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
Nanoscope Therapeutics Strengthens Clinical, Regulatory Expertise with Appointment of Chief Medical Officer
by Lance Murray | Sep 22, 2023
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
by Lance Murray |
Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
by David Seeley |
Jun 22, 2021
Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.
MORE►
by Lance Murray |
Dec 29, 2017
Discoveries and breakthroughs happen all the time in North Texas laboratories and institutions. Here are some of their stories.
MORE►
